Sarepta stock falls on FDA gene therapy Elevidys comment
Douglas Ingram, President and CEO of Sarepta Therapeutics Inc. , Through the FORBES Healthcare summit in New York, on Tuesday, December 5, 2023.
Michael Nagil Bloomberg Gety footage
shares Sarepta treatments Greater than 30 % decreased on Friday, when the way forward for adopted genetic remedy appeared.
The Meals and Drug Administration will ask the corporate to cease all remedy shipments voluntarily, an individual aware of the CNBC command.
Sarpta instructed CNBC that she had not heard from the Meals and Drug Administration.
Individually, Marti Macari, Commissioner of FDA Tell Bloomberg News The company research whether or not the corporate’s genetic remedy ought to stay in the marketplace.
The Meals and Drug Administration (FDA) is investigating the demise of two sufferers related to Elevidys. The corporate additionally reported a 3rd demise linked to a separate experimental genetic remedy.
The shares of the corporate now decreased greater than 87 % this 12 months.
– Angelica Peoples of CNBC contributed to this report
This story is creating. Please test once more for updates.
2025-07-18 17:28:00
